Century Therapeutics, Inc.
NASDAQ:IPSC
1.26 (USD) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 2.235 | 5.199 | 0 | 0 | 0 |
| Cost of Revenue
| 13.044 | 10.071 | 4.582 | 1.754 | 0.249 |
| Gross Profit
| -10.809 | -4.872 | -4.582 | -1.754 | -0.249 |
| Gross Profit Ratio
| -4.836 | -0.937 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 92.71 | 107.173 | 75.648 | 39.681 | 14.266 |
| General & Administrative Expenses
| 34.706 | 31.857 | 19.235 | 9.495 | 5.767 |
| Selling & Marketing Expenses
| -13.044 | 0 | 0 | 0 | 0 |
| SG&A
| 21.662 | 31.857 | 19.235 | 9.495 | 5.767 |
| Other Expenses
| -0.383 | 4.42 | 0.377 | 0.704 | 1.21 |
| Operating Expenses
| 114.372 | 139.03 | 94.883 | 49.176 | 20.033 |
| Operating Income
| -125.181 | -133.831 | -94.883 | -53.898 | -245.979 |
| Operating Income Ratio
| -56.009 | -25.742 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -9.611 | 2.99 | -0.898 | 0.323 | 1.21 |
| Income Before Tax
| -134.792 | -130.841 | -95.781 | -53.575 | -244.769 |
| Income Before Tax Ratio
| -60.31 | -25.167 | 0 | 0 | 0 |
| Income Tax Expense
| 1.881 | 0.091 | 0.043 | 1.085 | 1.21 |
| Net Income
| -136.673 | -130.932 | -95.824 | -54.66 | -245.979 |
| Net Income Ratio
| -61.151 | -25.184 | 0 | 0 | 0 |
| EPS
| -2.3 | -2.27 | -1.74 | -1 | -4.49 |
| EPS Diluted
| -2.3 | -2.27 | -1.74 | -1 | -4.49 |
| EBITDA
| -112.137 | -121.296 | -94.506 | -47.07 | -18.574 |
| EBITDA Ratio
| -50.173 | -23.331 | 0 | 0 | 0 |